press release-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

news press release media report

year:

select

press release

13 janurary 2022

enrollment completed in phase ii clinical study of kn026 combined with kn046 interim analysis expected in the second quarter of 2022
12 janurary 2022

alphamab oncology received the most valuable pharmaceutical and medical company award alphamab oncology has received the award for two consecutive years since it was listed in hong kong in december 2019, demonstrating the long-term value of the company's continued pioneering innov...
05 janurary 2022

ind approved for pivotal clinical study of her2 bispecific antibody kn026 combined with chemotherapy in gastric cancer bring hope to patients with advanced gastric cancer who are in urgent need of new treatment options.
26 december 2021

alphamab oncology once again ranked in the top 100 chinese pharmaceutical innovative enterprises list alphamab oncology was listed for the third consecutive year.
23 december 2021

alphamab oncology announced first patient dosed in the u.s. in a phase ii pivotal clinical study of kn046 study to evaluate efficacy, safety and tolerability of kn046 in subjects with advanced thymic carcinoma.
21 december 2021

csco tumor immunotherapy summit & envafolimab china launch meeting held top experts in the national oncology clinical community discussed the clinical value of immunotherapy, the efficacy and safety of envafolimab.
16 december 2021

new option for 30-second dosing! first prescriptions for the world's first subcutaneously injected pd-l1 antibody! the first batch of prescriptions for the world's first subcutaneously injected pd-l1 antibody envafolimab has been implemented across the country.
10 december 2021

press conference on the launch of envafolimab, the world's first subcutaneously injected pd-l1 antibody providing a new treatment option for cancer patients in china
09 december 2021

posters highlighting clinical data of kn026 presented at sabcs 2021 two posters highlighting data from two clinical study of the anti-her2 bispecific antibody kn026 were presented at the sabcs 2021.
03 december 2021

envafolimab, the world’s first subcutaneously injected pd-l1 antibody approved, is shipped nationwide! start a new era of 30-second dosing for making cancer manageable and curable.